1110 — Kingworld Medicines Balance Sheet
0.000.00%
- HK$317.48m
- HK$604.67m
- CNY1.06bn
- 36
- 84
- 18
- 42
Annual balance sheet for Kingworld Medicines, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 261 | 198 | 256 | 194 | 250 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 297 | 280 | 237 | 235 | 203 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 715 | 640 | 624 | 589 | 608 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 168 | 210 | 300 | 386 | 424 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 1,255 | 1,214 | 1,263 | 1,338 | 1,416 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 556 | 474 | 542 | 464 | 515 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 664 | 597 | 648 | 719 | 776 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 592 | 617 | 616 | 619 | 640 |
| Total Liabilities & Shareholders' Equity | 1,255 | 1,214 | 1,263 | 1,338 | 1,416 |
| Total Common Shares Outstanding |